R. Michael Carruthers - 23 Jan 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Financial Officer
Signature
/s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers
Issuer symbol
EWTX
Transactions as of
23 Jan 2024
Net transactions value
-$1,246,059
Form type
4
Filing time
25 Jan 2024, 16:46:26 UTC
Previous filing
18 Aug 2023
Next filing
03 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $173,700 +90,000 +310% $1.93* 119,024 23 Jan 2024 Direct F1
transaction EWTX Common Stock Sale $1,419,759 -90,000 -76% $15.78 29,024 23 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -90,000 -40% $0.000000 137,058 23 Jan 2024 Common Stock 39,488 $1.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on February 23, 2023.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.